Shares of Conatus Pharmaceuticals Inc. (CNAT) are higher by 23.34% to $3.54 in pre-market trading on Wednesday after the company announced positive results with its experimental drug, Emricasan, in initial stage of Phase 2 liver cirrhosis clinical trial. Conatus said the drug showed consistent improvement across additional liver disease biomarkers in the overall patient population. […]
View the full post at: Morning Buzz: Conatus (CNAT), Apple (AAPL), Yahoo (YHOO), Chipotle Mexican Grill (CMG)